RhoVac's market research shows great potential for a cancer vaccine preventing recurrence of metastatic disease in multiple cancers
Lund, November 29, 2021. RhoVac AB ("RhoVac") is a Swedish immuno-oncology company, whose drug candidate, RV001 (onilcamotide), is a cancer vaccine that aims to prevent recurrence of cancer through the formation of metastases after initial surgery or radiation therapy. The drug candidate is in the final stages of the BraVac international clinical phase IIb study in prostate cancer. In the event of a successful outcome it is considered highly likely that onilcamotide will be suitable for development also in other cancers. The company announces today that it has completed a market survey of